• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

局部嵌合抗原受体 T 细胞治疗：实体瘤全身性免疫的点火钥匙。

Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors.

机构信息

Department of Surgical Oncology and Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

出版信息

Cancer Cell. 2022 Jun 13;40(6):569-574. doi: 10.1016/j.ccell.2022.04.006. Epub 2022 Apr 28.

DOI:10.1016/j.ccell.2022.04.006
PMID:35487216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9197990/
Abstract

The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional delivery of CAR T cells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.

摘要

嵌合抗原受体 (CAR) T 细胞疗法在实体瘤中的成功，与血液恶性肿瘤不同，受到肿瘤浸润不足以及 T 细胞功能障碍和衰竭的限制。在实体瘤患者中进行 CAR T 细胞的区域性递送是安全且可行的；促进浸润、增殖和迁移；并引发具有功能持续性的全身免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3410/9197990/d20872c34120/nihms-1809327-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3410/9197990/d20872c34120/nihms-1809327-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3410/9197990/d20872c34120/nihms-1809327-f0001.jpg

相似文献

1
Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors.局部嵌合抗原受体 T 细胞治疗：实体瘤全身性免疫的点火钥匙。
Cancer Cell. 2022 Jun 13;40(6):569-574. doi: 10.1016/j.ccell.2022.04.006. Epub 2022 Apr 28.
2
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.嵌合抗原受体 T 细胞免疫疗法治疗实体瘤的展望。
Front Immunol. 2018 May 22;9:1104. doi: 10.3389/fimmu.2018.01104. eCollection 2018.
3
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.实体瘤的嵌合抗原受体 T 细胞：在肿瘤微环境中寻找、浸润和存活的新策略。
Front Immunol. 2019 Feb 5;10:128. doi: 10.3389/fimmu.2019.00128. eCollection 2019.
4
Making CAR T Cells a Solid Option for Solid Tumors.将 CAR T 细胞疗法变为实体瘤的可靠选择。
Front Immunol. 2018 Nov 8;9:2593. doi: 10.3389/fimmu.2018.02593. eCollection 2018.
5
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.嵌合抗原受体修饰 T 细胞治疗实体瘤的前景。
Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3.
6
Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.嵌合抗原受体 T 细胞疗法：T 细胞内在、T 细胞外在和治疗限制的当前观点。
Cancer J. 2023;29(1):28-33. doi: 10.1097/PPO.0000000000000636.
7
Engineering CAR-T Cells for Next-Generation Cancer Therapy.工程化 CAR-T 细胞用于下一代癌症治疗。
Cancer Cell. 2020 Oct 12;38(4):473-488. doi: 10.1016/j.ccell.2020.07.005. Epub 2020 Jul 30.
8
Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.嵌合抗原受体 T 细胞治疗实体瘤的临床研究：经验总结与未来方向。
Pharmacol Ther. 2020 Jan;205:107419. doi: 10.1016/j.pharmthera.2019.107419. Epub 2019 Oct 16.
9
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.针对实体瘤的嵌合抗原受体 T 细胞（CAR-T）癌症免疫疗法面临的障碍。
Sci China Life Sci. 2016 Apr;59(4):340-8. doi: 10.1007/s11427-016-5027-4. Epub 2016 Mar 11.
10
Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?CAR-T 细胞免疫疗法治疗实体瘤的综合临床评估：前进之路还是死胡同？
J Cancer Res Clin Oncol. 2023 Jun;149(6):2709-2734. doi: 10.1007/s00432-022-04547-4. Epub 2022 Dec 24.

引用本文的文献

1
CAR-T cell therapy for glioblastoma: advances, challenges, and future directions.胶质母细胞瘤的嵌合抗原受体T细胞疗法：进展、挑战与未来方向
Ann Med Surg (Lond). 2025 Jul 18;87(9):5743-5756. doi: 10.1097/MS9.0000000000003607. eCollection 2025 Sep.
2
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.推进基于嵌合抗原受体（CAR）的实体瘤细胞疗法：挑战、治疗策略及展望
Mol Cancer. 2025 Jul 7;24(1):191. doi: 10.1186/s12943-025-02386-8.
3
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.

本文引用的文献

1
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.用于 H3K27M 突变型弥漫性中线脑胶质瘤的 GD2-CAR T 细胞疗法。
Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7.
2
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.一项在恶性胸膜疾病患者中联合抗 PD-1 药物 Pembrolizumab 进行局部间皮素靶向 CAR T 细胞治疗的 I 期临床试验。
Cancer Discov. 2021 Nov;11(11):2748-2763. doi: 10.1158/2159-8290.CD-21-0407. Epub 2021 Jul 15.
3
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
嵌合抗原受体T细胞疗法在脑恶性肿瘤中的应用：细胞转运与存活面临的障碍
Front Immunol. 2025 Jun 19;16:1596499. doi: 10.3389/fimmu.2025.1596499. eCollection 2025.
4
Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer.利用Delta样配体3：为难治性小细胞肺癌的生物标志物发现与下一代免疫疗法架起桥梁。
Front Immunol. 2025 May 27;16:1592291. doi: 10.3389/fimmu.2025.1592291. eCollection 2025.
5
CD70 CAR-T cells empowered by TS-2021 through ex vivo transduction show potent antitumor efficacy against glioblastoma.通过体外转导由TS-2021赋能的CD70嵌合抗原受体T细胞（CD70 CAR-T细胞）对胶质母细胞瘤显示出强大的抗肿瘤功效。
J Exp Clin Cancer Res. 2025 Jun 5;44(1):173. doi: 10.1186/s13046-025-03431-6.
6
Novel strategies to manage CAR-T cell toxicity.管理嵌合抗原受体T细胞毒性的新策略。
Nat Rev Drug Discov. 2025 May;24(5):379-397. doi: 10.1038/s41573-024-01100-5. Epub 2025 Feb 3.
7
XCL1-secreting CEA CAR-T cells enhance endogenous CD8 T cell responses to tumor neoantigens to confer a long-term antitumor immunity.分泌XCL1的癌胚抗原嵌合抗原受体T细胞增强内源性CD8 T细胞对肿瘤新抗原的反应，以赋予长期抗肿瘤免疫力。
J Immunother Cancer. 2025 Jan 6;13(1):e010581. doi: 10.1136/jitc-2024-010581.
8
Endovascular surgical neuro-oncology: advancing a new subspecialty.血管内神经外科学：推进一个新的亚专业。
J Neurooncol. 2024 Oct;170(1):31-40. doi: 10.1007/s11060-024-04782-4. Epub 2024 Sep 2.
9
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.最大化CAR-T细胞免疫疗法治疗癌症疗效的输注与给药策略。
Exp Hematol Oncol. 2024 Jul 26;13(1):70. doi: 10.1186/s40164-024-00542-2.
10
Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment.靶向间皮素的嵌合抗原受体T细胞疗法在实体瘤治疗中的应用。
Discov Oncol. 2024 Jul 18;15(1):289. doi: 10.1007/s12672-024-01159-x.
局部区域性输注 HER2 特异性 CAR T 细胞治疗儿童和青年复发性或难治性中枢神经系统肿瘤：一项中期分析。
Nat Med. 2021 Sep;27(9):1544-1552. doi: 10.1038/s41591-021-01404-8. Epub 2021 Jul 12.
4
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.局部给予 B7-H3 靶向嵌合抗原受体 T 细胞治疗胚胎性肿瘤/横纹肌样瘤。
Nat Med. 2020 May;26(5):712-719. doi: 10.1038/s41591-020-0821-8. Epub 2020 Apr 27.
5
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.CRISPR-Cas9 敲除 PD-1 增强了通用 EGFRvIII CAR T 细胞在人胶质母细胞瘤临床前模型中的活性。
J Immunother Cancer. 2019 Nov 14;7(1):304. doi: 10.1186/s40425-019-0806-7.
6
Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.在清除小鼠中枢神经系统淋巴瘤过程中 CAR T 细胞动态的长期体内显微镜观察。
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24275-24284. doi: 10.1073/pnas.1903854116. Epub 2019 Nov 11.
7
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
8
Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.嵌合抗原受体 T 细胞过继转移 IL13Rα2 特异性受体可在胶质母细胞瘤中创造促炎环境。
Mol Ther. 2018 Apr 4;26(4):986-995. doi: 10.1016/j.ymthe.2018.02.001. Epub 2018 Feb 8.
9
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.针对结直肠癌中 TAG-72 的嵌合抗原受体 (CAR)-T 细胞的安全性、肿瘤转移和免疫原性。
J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. eCollection 2017.
10
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞疗法后胶质母细胞瘤的消退
N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497.